Skip to main content
Globe And Street

The world, accounted for.

Global business and finance

SectionsMenuClose

Science Corporation raises $400 million at $3.5 billion valuation

The medical technology startup plans to use the Series D funding to pursue U.S. approval for its PRIMA vision device.

Illustration of an implantable medical chip alongside wearable vision technology
Photo: TechCrunch

Science Corporation has secured $400 million in Series D financing, the company said in a blog post. The deal gave the startup a valuation of $3.5 billion, according to a person familiar with the transaction.

Participants included Tenet Healthcare, PLC Neurotech, Khosla Ventures, 885 Capital, the Ackman Oxman Institute and Y Combinator. Former Neuralink president Max Hodak founded Science in 2021.

Science plans to put the funding toward bringing its first product, PRIMA, to the United States. The device combines wearable and implantable technology to help restore some vision for people with age-related macular degeneration. It has European approval and is available in Germany.

The company intends to pursue the FDA's Humanitarian Device Exemption, a pathway allowing experimental medical technology to treat rare conditions. Science has persuaded the regulator that advanced macular degeneration affecting both eyes is sufficiently uncommon to qualify for an application. Hodak also said PRIMA is being tested in patients with Stargardt disease, another condition that causes blindness.

Beyond PRIMA, Science is developing a sensor combining cultured neurons with silicon to connect directly with the brain. It is designing initial trials in humans with Murat Günel, a Yale neurosurgery professor. Günel said the technology could potentially treat Parkinson's disease and other brain illnesses and injuries.

Editorial policyReport a mistake

About the author

Lucas Almeida

Companies and Deals Editor

Edits and reviews corporate news (earnings, leadership changes, layoffs, product launches) and deal news (IPOs, mergers and acquisitions, buyouts and funding rounds).